The Asia Harm Reduction Forum held its fifth annual conference on October 28, 2022. As a non-profit and interdisciplinary organization, it empowers and charges individuals, communities, and governments to make informed decisions related to health and provides global initiatives for reducing different types of harm. The forum presents the latest perspectives on harm reduction and encourages reductions on a global scale.
To inform the public about the benefits of reducing harmful practices for a healthier lifestyle, leading experts from various fields including decision-making, science, business, and education have presented the latest research and studies, with a particular focus on reducing the harm caused by tobacco.
During the climax of the forum, speakers and leaders in attendance drafted the "2022 Manila Declaration." They called on signatory countries of the World Health Organization (WHO) and representatives of the Framework Convention on Tobacco Control (FCTC) to follow scientific evidence and reduce the harm caused by tobacco while discouraging its use, and to encourage the use of safer nicotine products as alternatives.
The 10th Conference of Parties (COP10) of the WHO Framework Convention on Tobacco Control is only a year away from being held in Panama. In this significant global conference, representatives will discuss safer nicotine products and make recommendations.
Nancy Loucas, the executive coordinator of the Asia Pacific Advocacy Network (CAPHRA), has stated that providing false information as "guidance" to signing countries by the WHO Framework Convention on Tobacco Control (WHO FCTC) and its affiliated organizations is dangerous. Every year, there are 8 million deaths among adults caused by unsafe tobacco products, and the WHO FCTC has failed and is continuing to fail.
The Philippines is providing a platform for discussion, accessibility of information, and forward-thinking legislation, thus continuing to lead the efforts in reducing tobacco harm among its Asian neighbors.
One of the most hotly debated topics during the 2022 Asia Harm Reduction Forum was the passing of Republic Act No. 1190, also known as the Vaporized Nicotine and Non-Nicotine Products Regulation Act. The forum discussed the successful implementation of the regulation at a national level and its impact on domestic consumers.
Robert Ace Barbers, the representative of the 2nd district of Surigao del Norte and a member of the Philippine Congress, played a key role in authoring the "Vape Bill." In a pre-recorded speech, he added to the importance of the event by emphasizing that "the most effective way to reduce harm is through legislation that makes it a national policy." This demonstrated his understanding of the value of decision-making methods that reduce harm.
Meanwhile, Clarisse Virgino, the Philippine representative of the Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA), praised Philippine legislators for advocating harm reduction in their legislation.
2FIRSTS will continue to report on this topic and provide updates on the "2FIRSTSAPP" platform. Scan the QR code below to download the app.
The e-cigarette law has presented new possibilities for harm reduction alternatives in the country. This is just the first step in creating a healthier and safer environment for everyone. We hope our legislators will continue to seek different ways to reduce harm within their legal authority to protect the welfare of their citizens," said Ms. Virgino.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
